Remodeling of the heart due to pressure overload is a significant contributor to cardiac disease worldwide, impacting cardiac function through a multitude of harmful changes. Different drugs are employed in treatment of this condition, and in the current article we investigate the effects of a new drug, Sacubitril/Valsartan, comparing it to an established therapeutic modality. We found that Sacubitril/Valsartan prevents several of the deleterious changes, affecting both growth of cardiac cells and the ability of the heart to relax. The treatment did however not improve changes in contractile function of the heart, highlighting the need for further therapeutic developments.
ESC Heart Fail, 8 (2), 918-927
PubMed 33497525 DOI 10.1002/ehf2.13177
